Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 198

1.

Exacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexy.

Ristanovic RK, Liang H, Hornfeldt CS, Lai C.

Sleep Med. 2009 Apr;10(4):416-21. doi: 10.1016/j.sleep.2008.04.004. Epub 2008 Aug 26.

PMID:
18753005
[PubMed - indexed for MEDLINE]
2.

Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy.

U.S. Xyrem Multicenter Study Group.

Sleep Med. 2004 Mar;5(2):119-23.

PMID:
15033130
[PubMed - indexed for MEDLINE]
4.

Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.

[No authors listed]

Prescrire Int. 2007 Jun;16(89):98-101.

PMID:
17582923
[PubMed - indexed for MEDLINE]
5.
6.

A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.

Xyrem International Study Group.

J Clin Sleep Med. 2005 Oct 15;1(4):391-7.

PMID:
17564408
[PubMed - indexed for MEDLINE]
7.

Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients.

Xyrem International Study Group.

Sleep Med. 2005 Sep;6(5):415-21.

PMID:
16099718
[PubMed - indexed for MEDLINE]
8.

Rebound cataplexy after withdrawal from antidepressants.

Broderick M, Guilleminault C.

Sleep Med. 2009 Apr;10(4):403-4. doi: 10.1016/j.sleep.2008.06.004. Epub 2008 Aug 8. No abstract available.

PMID:
18692440
[PubMed - indexed for MEDLINE]
9.

The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms.

[No authors listed]

J Toxicol Clin Toxicol. 2003;41(2):131-5.

PMID:
12733850
[PubMed - indexed for MEDLINE]
10.

Antidepressants and suicidal behaviour in unipolar depression.

Yerevanian BI, Koek RJ, Feusner JD, Hwang S, Mintz J.

Acta Psychiatr Scand. 2004 Dec;110(6):452-8.

PMID:
15521830
[PubMed - indexed for MEDLINE]
11.

Antidepressant discontinuation: a review of the literature.

Lejoyeux M, Adès J.

J Clin Psychiatry. 1997;58 Suppl 7:11-5; discussion 16. Review.

PMID:
9219488
[PubMed - indexed for MEDLINE]
12.

Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures.

Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH.

J Clin Psychopharmacol. 2008 Aug;28(4):411-7. doi: 10.1097/JCP.0b013e31817e0ecb.

PMID:
18626268
[PubMed - indexed for MEDLINE]
13.

Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.

Scrima L, Hartman PG, Johnson FH Jr, Hiller FC.

Biol Psychiatry. 1989 Aug;26(4):331-43.

PMID:
2669980
[PubMed - indexed for MEDLINE]
14.

A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy.

[No authors listed]

Sleep. 2003 Feb 1;26(1):31-5.

PMID:
12627729
[PubMed - indexed for MEDLINE]
15.

Emerging drugs for narcolepsy.

Abad VC, Guilleminault C.

Expert Opin Emerg Drugs. 2004 Nov;9(2):281-91. Review.

PMID:
15571485
[PubMed - indexed for MEDLINE]
16.

EFNS guidelines on management of narcolepsy.

Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, Pollmächer T, Reading P, Sonka K; EFNS Task Force.

Eur J Neurol. 2006 Oct;13(10):1035-48.

PMID:
16987156
[PubMed - indexed for MEDLINE]
17.

Antidepressant discontinuation syndromes.

Haddad PM.

Drug Saf. 2001;24(3):183-97. Review.

PMID:
11347722
[PubMed - indexed for MEDLINE]
18.

Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management.

Thorpy MJ.

CNS Drugs. 2006;20(1):43-50. Review.

PMID:
16396523
[PubMed - indexed for MEDLINE]
19.

Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors.

Peretti S, Judge R, Hindmarch I.

Acta Psychiatr Scand Suppl. 2000;403:17-25. Review.

PMID:
11019931
[PubMed - indexed for MEDLINE]
20.

Unusually prolonged rebound cataplexy after withdrawal of fluoxetine.

Poryazova R, Siccoli M, Werth E, Bassetti CL.

Neurology. 2005 Sep 27;65(6):967-8. No abstract available.

PMID:
16186554
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk